Literature DB >> 6835335

Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia nervosa.

P W Gold, W Kaye, G L Robertson, M Ebert.   

Abstract

Previous studies have indicated that many patients with anorexia nervosa have defects in urinary concentration or dilution suggestive of abnormal secretion of the antidiuretic hormone arginine vasopressin. To explore this possibility, we examined the response of plasma vasopressin to intravenous hypertonic saline in anorexic patients before and after correction of their weight loss. We also measured basal levels of the hormone in the cerebrospinal fluid. In all four subjects studied before correction of weight loss, the response to hypertonic saline was abnormal: in one, the plasma level of arginine vasopressin increased subnormally relative to the plasma sodium level; in the other three, it fluctuated erratically, with no relation to plasma sodium. These defects persisted in the three patients studied three to four weeks after recovery of body weight. In two patients who were initially studied when they were underweight, the defects were gone six months after recovery; in five of seven other patients studied at least six months after recovery but not while they were underweight, the response was normal. Abnormalities in the osmoregulation of plasma arginine vasopressin were not accounted for by nonosmotic stimuli and were almost always associated with an absolute increase in the level of arginine vasopressin in the cerebrospinal fluid or a reversal of the normal (less than 1.0) cerebrospinal fluid/plasma ratio of arginine vasopressin. These results indicate that most if not all patients with anorexia nervosa have abnormal levels of arginine vasopressin in their plasma and cerebrospinal fluid that are corrected very slowly with weight gain. The cause and consequences of these abnormalities remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6835335     DOI: 10.1056/NEJM198305123081902

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  18 in total

Review 1.  Stress-related reproductive failure.

Authors:  E R Barnea; J Tal
Journal:  J In Vitro Fert Embryo Transf       Date:  1991-02

Review 2.  The endocrine manifestations of anorexia nervosa: mechanisms and management.

Authors:  Melanie Schorr; Karen K Miller
Journal:  Nat Rev Endocrinol       Date:  2016-11-04       Impact factor: 43.330

3.  Endocrinological differentiation of primary hypothalamic and pituitary disease.

Authors:  E E Müller
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

4.  Fluid intake, personality and behaviour in patients with eating disorders.

Authors:  S F Abraham; S Hart; G Luscombe; J Russell
Journal:  Eat Weight Disord       Date:  2006-03       Impact factor: 4.652

5.  Clinical problems in adolescent medicine.

Authors:  L J D'Angelo; J Farrow
Journal:  J Gen Intern Med       Date:  1989 Jan-Feb       Impact factor: 5.128

Review 6.  Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment.

Authors:  F Brambilla
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 7.  Hypoglycaemia and anorexia nervosa.

Authors:  D Mattingly; S Bhanji
Journal:  J R Soc Med       Date:  1995-04       Impact factor: 5.344

Review 8.  Renal complications in anorexia nervosa.

Authors:  Chantal Stheneur; Sebastien Bergeron; Anne-Laure Lapeyraque
Journal:  Eat Weight Disord       Date:  2014-07-06       Impact factor: 4.652

Review 9.  The endocrinopathies of anorexia nervosa.

Authors:  Lisa S Usdan; Lalita Khaodhiar; Caroline M Apovian
Journal:  Endocr Pract       Date:  2008-11       Impact factor: 3.443

10.  Plasma sodium level is associated with bone loss severity in women with anorexia nervosa: a cross-sectional study.

Authors:  Elizabeth A Lawson; Pouneh K Fazeli; Genevieve Calder; Hannah Putnam; Madhusmita Misra; Erinne Meenaghan; Karen K Miller; Anne Klibanski
Journal:  J Clin Psychiatry       Date:  2012-11       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.